Last reviewed · How we verify
Td-pur inj
Td-pur is an immunotherapeutic injection designed to stimulate anti-tumor immune responses through a purified tumor-associated antigen or dendritic cell-based approach.
Td-pur is an immunotherapeutic injection designed to stimulate anti-tumor immune responses through a purified tumor-associated antigen or dendritic cell-based approach. Used for Cancer immunotherapy (specific indication not publicly confirmed).
At a glance
| Generic name | Td-pur inj |
|---|---|
| Sponsor | Boryung Biopharma Co., Ltd. |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details are limited in public sources, Td-pur appears to be an investigational immunotherapy targeting tumor-associated antigens or utilizing dendritic cell technology to enhance T-cell mediated anti-tumor immunity. The drug is in Phase 3 development by Boryung Biopharma, a South Korean biopharmaceutical company, suggesting it is being evaluated for oncologic indications.
Approved indications
- Cancer immunotherapy (specific indication not publicly confirmed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |